Form 4: Amneal Pharmaceuticals Director, John Kiely, Acquires 40,258 Restricted Stock Units

Director John Kiely acquired 40,258 restricted stock units of Amneal Pharmaceuticals, Inc. on May 2, 2024.

Summary

• On May 2, 2024, John Kiely, a director of Amneal Pharmaceuticals, Inc., acquired 40,258 restricted stock units (RSUs) representing a contingent right to receive one share of the Issuer's Class A Common Stock.
• The RSUs vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
• Following the transaction, Kiely directly owns 40,258 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing a common form of executive compensation. The acquisition of RSUs by a director is generally viewed as a positive, but it's not a major event.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon future events, specifically the timing of the company's annual meetings and the anniversary of the grant date.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a grant of restricted stock units to a director, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of restricted stock units by a director could have a slightly positive impact on shareholder sentiment, as it indicates confidence in the company's future.

Key Dates